RTF2

Across TCGA pan-cancer cohorts, RTF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RTF2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RTF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RTF2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and COAD show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where RTF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.922	0.765	.012	12	view →
CCRCC	OS	Median	All	0.767	0.912	.019	9	view →
UCEC	DFS	Tertile	All	0.859	0.975	.042	8	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.909	.046	6	view →
HNSC	OS	Median	III,IV	0.449	1.000	.023	2	view →
GBM	OS	Tertile	All	0.644	0.816	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RTF2–LUAD (OS)

Open the LUAD breakdown →